middle.news
Prescient Therapeutics Boosts PTX-100 Trial Sites and Strengthens Drug Profile with CSIRO Data
10:04am on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
Prescient Therapeutics Boosts PTX-100 Trial Sites and Strengthens Drug Profile with CSIRO Data
10:04am on Thursday 30th of April, 2026 AEST
Key Points
Global expansion to 12 Phase 2a trial sites with 18 patients enrolled
CSIRO collaboration reveals strong target binding of PTX-100
Cash and term deposits total $11.93 million after R&D tax refund
Deferred R&D invoices expected to impact next quarter’s cash flow
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE